Best Recombinant Proteins CDMOs in United States
· updated as new inspection, certificate, and trial data enters the platform
9
CDMOs tracked
9
Fully scored
6
With FDA records
37
FDA inspections
124
EMA/MHRA GMP certs
2
Warning letters
Recombinant protein CDMOs make therapeutic proteins, enzymes, and growth factors using microbial (E. coli, yeast) or mammalian (CHO) expression. Choice of host turns on post-translational modification needs, scale economics, and downstream-purification complexity.
Selecting a recombinant protein CDMO turns on host-system experience, validated bioreactor scale, downstream purification and analytics, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 12 NAI (no action), 23 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: Denmark (52), United States (30), Germany (21), UNITED KINGDOM (17), Lithuania (8).
Last updated 2026-10-30. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 35 open roles
|
78.5 | 99.8 | 4 insp · 27 GMP | Available | 2 programs |
| 2 |
PB
Pharmaron
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 5 insp · 1 GMP | Available | 0 programs |
| 3 |
FD
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 29 open roles
|
84.8 | 100.0 | 0 insp · 35 GMP | 0 programs | |
| 4 |
KB
KBI Biopharma
Durham, NC · Boulder, CO
Hiring · 85 open roles
|
84.1 | 98.5 | 2 insp · 1 GMP | Limited | 0 programs |
| 5 |
WK
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
Hiring · 7 open roles
|
81.6 | 100.0 | 1 insp · 13 GMP | — | 0 programs |
| 6 |
NW
Northway Biotech
Vilnius, LT; Waltham (MA), USA
Hiring · 13 open roles
|
80.8 | 100.0 | 0 insp · 8 GMP | Available | 0 programs |
| 7 |
Cytovance Biologics
Oklahoma City, OK
|
78.6 | 98.2 | 1 insp · 0 GMP | Available | 0 programs |
| 8 |
Catalent
Tampa, FL
Hiring · 296 open roles
|
68.6 | 65.2 | 24 insp · 39 GMP | — | 0 programs |
| 9 |
BN
Bionova Scientific
Fremont, CA
|
59.0 | — | — | — | 0 programs |
What to evaluate in a Recombinant Proteins CDMO
Expression host & scale
Microbial hosts (E. coli, P. pastoris) suit non-glycosylated proteins; mammalian (CHO) is the workhorse for glycoproteins. Confirm validated bioreactor scale and the CDMO's experience with your target.
Purification & analytics
Downstream complexity (multiple chromatography steps, refolding for E. coli) drives cost and timeline. Ask about the orthogonal analytics package — purity, identity, potency.
Regulatory readiness
Clean FDA 483 history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & commercial readiness
For programs heading to BLA, evaluate validated commercial scale and any approved-product track record.
FDA jurisdiction — how the ranking scores US-based CDMOs
The Signal Score's Quality Compliance pillar (35% of the composite) is dominated by FDA inspection data for US-based CDMOs: Establishment Inspection Report classifications (NAI, VAI, OAI), Form 483 observation counts, and Warning Letter history. For a CDMO whose primary facility footprint is US, this pillar carries direct weight — an inspection on the site slated for a sponsor's program applies without translation. For CDMOs with mixed US + international facility footprint, the ranking reflects the composite regulatory posture; sponsors evaluating for a specific program should verify inspection history on the exact US site under consideration via that CDMO's profile page.
Which US CDMOs also cover EU and UK regulatory geographies?
Many top-tier US-based CDMOs maintain EU (EMA) and UK (MHRA) GMP certification for facilities used to supply EU and UK trials or commercial markets. The Signal Score's Quality Compliance pillar includes EMA + MHRA certificate density as a component — a US-headquartered CDMO with dense EU/UK certificates typically ranks higher on this pillar than a US-only competitor. Sponsors running dual-jurisdiction programs should cross-check the individual CDMO profile pages for specific certificate coverage; the Europe region ranking surfaces CDMOs that also appear in the European jurisdiction ranking, indicating multi-region regulatory posture.
How CDMO Signal identifies US manufacturing presence
Region attribution is derived from each CDMO's declared facility locations in our directory. A CDMO's facility list is validated against corporate filings, press releases, and — where public — the FDA facility registration (FEI number lookups). Region matching is done at the country level: a US state name or two-letter abbreviation in the facility list places the CDMO in the US region. CDMOs with US + international sites appear in every applicable region ranking, which reflects operational reality — such a CDMO is a legitimate candidate for programs in any of those jurisdictions.
Recombinant Proteins CDMOs — Frequently Asked Questions
Who are the top Recombinant Proteins CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Recombinant Proteins CDMOs include AGC Biologics, Pharmaron, FUJIFILM Diosynth Biotechnologies. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Recombinant Proteins CDMOs have FDA inspection records?
CDMO Signal tracks 6 Recombinant Proteins CDMOs with FDA inspection records and 124 EMA/MHRA GMP certificates across the group.
What should I look for in a recombinant protein CDMO?
Confirm expression-host experience for your target (microbial vs mammalian), validated bioreactor scale, a strong downstream-purification platform, qualified analytics, and a clean FDA and EMA/MHRA record.
How is a recombinant protein CDMO different from a mAb CDMO?
There's significant overlap — mAbs are recombinant proteins. But mAb CDMOs are typically optimized for CHO-based platform processes, while general recombinant protein CDMOs handle a wider range of hosts and non-mAb formats (enzymes, growth factors, complex non-glycoproteins).
Related modalities